Provided is a nanophosphor having a core/double shell structure, the nanophosphor including a upconversion core including a Yb.sup.3+, Ho.sup.3+, and Ce.sup.3+ co-doped fluoride-based nanophosphor represented by Formula 1; a first shell surrounding at least a portion of the upconversion core, and comprising a Nd.sup.3+ and Yb.sup.3+ co-doped fluoride-based crystalline composition represented by Formula 2; and a second shell surrounding at least a portion of the first shell, and having paramagnetic properties represented by Formula 3.

A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.

The present disclosure relates to a nano complex material, a drug carrier including the same, a contract agent including the same, and a method for preparing the nano complex material, and the nano complex material of the present disclosure consists of a support and ionic particles and thus can exhibit excellent light absorbance, magnetic absorbance, storage stability, functionality as a contrast agent, and drug delivery performance, as well as low cytotoxicity.

A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.

Provided is a nanophosphor having a core/double shell structure, the nanophosphor including a upconversion core including a Yb.sup.3+, Ho.sup.3+, and Ce.sup.3+ co-doped fluoride-based nanophosphor represented by Formula 1; a first shell surrounding at least a portion of the upconversion core, and comprising a Nd.sup.3+ and Yb.sup.3+ co-doped fluoride-based crystalline composition represented by Formula 2; and a second shell surrounding at least a portion of the first shell, and having paramagnetic properties represented by Formula 3.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.

A vaginal preparation for the diagnosis of human female uterotubal patency and function, comprising particles having a nucleus absorbable by the tissues of the human body, and a coating for the nucleus which is dissolvable and non-absorbable by the tissues of the human body, inert and innocuous, the nucleus comprising at least one marker that can be released by the human body through an organic fluid, the coating being dissolvable and sensitive, for the purpose of the dissolution thereof, to time and/or changes in pH and/or temperature and/or another chemical/physical parameter along the route from the vaginal area to the tubal and pelvic area, the particles having a size, weight and ovoid shape corresponding approximately to those of spermatozoa.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.